Abbott Laboratories (NYSE:ABT) Updates Q1 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its first quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 1.120-1.180 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.550-5.800 EPS.

Abbott Laboratories Trading Down 9.4%

Shares of NYSE:ABT opened at $109.34 on Thursday. Abbott Laboratories has a 12 month low of $111.75 and a 12 month high of $141.23. The company’s fifty day simple moving average is $125.65 and its 200 day simple moving average is $128.68. The firm has a market cap of $190.12 billion, a price-to-earnings ratio of 13.74, a PEG ratio of 2.01 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 31.58%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Jefferies Financial Group upped their target price on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Daiwa Capital Markets lifted their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. Barclays lifted their target price on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Finally, Benchmark started coverage on Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $147.42.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Management issued 2026 guidance calling for 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55–$5.80 (≈10% growth at the midpoint), which signals confidence in recovery and future earnings growth. Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
• Positive Sentiment: Abbott received CE mark in Europe for the TactiFlex Duo ablation catheter, expanding its AFib device portfolio and supporting medtech growth in Europe. Abbott receives CE Mark for the TactiFlex Duo Ablation Catheter
• Positive Sentiment: Coverage pieces highlight Abbott’s steady dividend history and durable businesses (medical devices and diagnostics), supporting its appeal to income-focused investors. Want Decades of Passive Income? 2 Stocks to Buy.
• Neutral Sentiment: Q4 adjusted EPS of $1.50 matched analyst consensus (GAAP EPS $1.01); full-year 2025 adjusted EPS was $5.15 — earnings met expectations but offered limited upside surprise. Abbott Laboratories Trading Down 0.3%
• Neutral Sentiment: Analysts and previews were active around Q4 results, with some firms revising models ahead of the release — implies increased scrutiny but no consensus catalyst. Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Revenue missed estimates due to weakness in the diagnostics segment — ongoing volatility from lower COVID-19 testing demand and a reported freeze on foreign aid weighed on top-line results. This is the main near-term driver of selling pressure. Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Institutional Trading of Abbott Laboratories

Several hedge funds have recently modified their holdings of ABT. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC grew its holdings in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the period. United Bank boosted its position in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC increased its holdings in shares of Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.